Robin Stan, MD
Cardiology · Inglewood, CANPI 1912903048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 468 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Novartis at 25.3% of the total.
Across 468 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Merck$665
- Pfizer$642
- Amgen$593
- Boehringer Ingelheim$570
- Novo Nordisk$550
- plus $3K from 28 others
Across 2 payments — averaging $19,718 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$39K
What the payments were for
- Food & beverage$8,62499%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 146 | $2,194 |
| Merck | 28 | $665 |
| Pfizer | 41 | $642 |
| Amgen | 22 | $593 |
| Boehringer Ingelheim | 28 | $570 |
| Novo Nordisk | 25 | $550 |
| AstraZeneca | 28 | $502 |
| Johnson & Johnson | 25 | $419 |
| Bayer | 25 | $397 |
| Abbott | 9 | $281 |
| E.r. Squibb & Sons, L.L.C. | 15 | $244 |
| Esperion Therapeutics, Inc. | 16 | $237 |
| Alnylam Pharmaceuticals Inc. | 7 | $174 |
| Scpharmaceuticals Inc. | 8 | $173 |
| Akcea Therapeutics, Inc. | 5 | $167 |
| Kestra Medical Technology Services, Inc. | 3 | $86 |
| Gilead | 4 | $80 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Bridgebio Pharma, Inc. | 3 | $76 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $70 |
| Boston Scientific | 4 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Astellas Pharma US Inc | 3 | $52 |
| Edwards Lifesciences | 2 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Impulse Dynamics (USA) Inc. | 1 | $39 |
| Liquidia Technologies, Inc. | 1 | $31 |
| Heartflow, Inc. | 1 | $29 |
| Medtronic(2 entities) | 2 | $29 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $24 |
| Preventice Services, LLC | 1 | $22 |
| GSK | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$8,681 in reported general payments places this provider in the 85th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 192 | $237,443 |
| EliquisApixaban | 123 | $162,215 |
| XareltoRivaroxaban | 91 | $110,534 |
| JardianceEmpagliflozin | 66 | $66,103 |
| FarxigaDapagliflozin Propanediol | 46 | $62,883 |
| VerquvoVericiguat | 22 | $25,935 |
| OzempicSemaglutide | 26 | $21,800 |
| Repatha SureclickEvolocumab | 17 | $15,683 |
| Praluent PenAlirocumab | 16 | $9,500 |
| Ranolazine ErRanolazine | 26 | $5,293 |
| Atorvastatin Calcium | 493 | $3,610 |
| Amlodipine Besylate | 389 | $2,692 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 49 | $1,778 |
| Losartan Potassium | 191 | $1,774 |
| Carvedilol | 198 | $1,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $2,194 | $237,443192 claims |
| PfizerEliquis | $642 | $162,215123 claims |
| Johnson & JohnsonXarelto | $419 | $110,53491 claims |
| Boehringer IngelheimJardiance | $570 | $66,10366 claims |
| AstraZenecaFarxiga | $502 | $62,88346 claims |
| MerckVerquvo | $665 | $25,93522 claims |
| Novo NordiskOzempic | $550 | $21,80026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 cardiology providers in California.
Other cardiology in Inglewood
- Jack FarahiInglewood$10K
- Vernon HattoriInglewood$7K
- Norman LeporBeverly Hills$1.9M
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
- Bipin JoshiFresno$51K
- Anil ShahSanta Ana$49K
- Thomas KimSanta Ana$47K
- Hooman MadyoonLos Angeles$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.